Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.

导出原文传递

翻译打印收藏纠错

第一作者： Pavel,Klener

第一单位： First Medical Department, Charles University General Hospital in Prague, Czech Republic.

作者： Pavel,Klener ^[1] ; Eva,Fronkova ^[2] ; Marketa,Kalinova ^[3] ; David,Belada ^[4] ; Kristina,Forsterova ^[5] ; Robert,Pytlik ^[1] ; Petra,Blahovcova ^[1] ; Martin,Simkovic ^[1] ; David,Salek ^[5] ; Heidi,Mocikova ^[6] ; Vit,Prochazka ^[7] ; Andrea,Janikova ^[8] ; Martina,Vaskova ^[6] ; Ester,Mejstrikova ^[3] ; Roman,Kodet ^[3] ; Jan,Trka ^[4] ; Marek,Trneny ^[3]

作者单位： First Medical Department, Charles University General Hospital in Prague, Czech Republic. ^[1] Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Czech Republic. ^[2] Childhood Leukaemia Investigation Prague (CLIP), Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. ^[3] Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University Hospital in Motol, Prague, Czech Republic. ^[4] Fourth Department of Internal Medicine-Hematology, Charles University Hospital in Hradec Kralove and Faculty of Medicine in Hradec Kralove, Czech Republic. ^[5] Department of Hematology and Oncology, Masaryk University Hospital in Brno, Czech Republic. ^[6] Department of Internal Medicine and Haematology, Third Faculty of Medicine, Charles University Hospital Kralovske Vinohrady, Prague, Czech Republic. ^[7] Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic. ^[8]

关键词 PET-CT elderly patients maintenance rituximab mantle cell lymphoma minimal residual disease